Latest news

  • Start of a new era in fight against drug resistant TB

    Thursday 12 December

    WHO released a rapid communication on the treatment of drug resistant (DR) and extensively drug resistant (XDR) tuberculosis (TB). This puts an ‘end to tears’, for painful daily injections in […]

    Read more
  • 7th European Advanced Course in Clinical Tuberculosis

    Wednesday 20 November

    The 7th European Advanced Course in Clinical Tuberculosis (TB) offered an informative and interactive program with national and international speakers with a comprehensive experience in the field of clinical tuberculosis […]

    Read more
  • 3HP regimen soon to be accessible in Malawi

    Thursday 31 October

    KNCV Tuberculosis Foundation Malawi welcomes the substantial reduction in the price of the anti-tuberculosis drug rifapentine, announced today at the Union World Conference on Lung Health in India. “For people […]

    Read more
  • Important price reduction improves access to TB prevention

    Thursday 31 October

    KNCV Tuberculosis Foundation welcomes the announcement of a substantial reduction in the price of an anti-tuberculosis medicine through the support of Unitaid and the Global Fund, in partnership with the […]

    Read more
  • Innovative TB treatment support project kicks off in the Philippines

    Wednesday 25 September

    ASCENT aims to assist patients succeed in treatment using digital adherence technology. On World Lung Day, the innovative TB treatment support project ASCENT kicks off in the Philippines, making the […]

    Read more
  • Antacid helps tuberculosis bacteria to survive

    Sunday 1 September

    In 2017, some 10 million people suffered from tuberculosis and 1.6 million died of the disease. One reason why infection with Mycobacterium tuberculosis is so difficult to treat is that […]

    Read more
  • FDA approval of BPaL regimen an important breakthrough in TB control

    Wednesday 14 August

    The US Food & Drug Administration (FDA) today approved pretomanid for the treatment of highly drug-resistant forms of tuberculosis (TB) in a combination regimen known as BPaL. This regimen was […]

    Read more
  • ASCENT: Empowering patients through digital technology

    Tuesday 23 July

    GENEVA/THE HAGUE, The next three and a half years, KNCV Tuberculosis Foundation will lead the innovative ASCENT project, which stands for Adherence Support Coalition to End TB. This brand new […]

    Read more
  • Call to Action for awareness on AMR

    Thursday 20 June

    KNCV Tuberculosis Foundation is one of the civil society organizations that signs the Call to Action for awareness on antimicrobial resistance (AMR) in the Netherlands. Kitty van Weezenbeek, director of […]

    Read more
  • Wolfheze Workshops 2019: inspiring knowledge exchange & concrete steps forward

    Tuesday 28 May

    KNCV Tuberculosis Foundations can look back at an inspiring edition of the Wolfheze Workshops 2019 (15-17 May). In Scheveningen 160 TB experts from over 40 countries from Western Europe, Eastern […]

    Read more
  • Unique gathering of TB and HIV experts in Scheveningen

    Wednesday 15 May

    Biennial Wolfheze Workshops focuses on alarming tandem of infectious diseases THE HAGUE, 15 May 2019 International experts in the field of tuberculosis (TB) and HIV control meet today in Scheveningen […]

    Read more
  • Dutch civil society calls upon increase of Dutch commitment to the Global Fund

    Friday 12 April

    The Hague – This week, KNCV Tuberculosis Foundation, in cooperation with Aidsfonds and nine other Dutch civil society organisations* called upon the Dutch Minister for Trade and Development Cooperation, Sigrid […]

    Read more